Saudi Arabia Diabetes Drug Market Size, Trends, and Forecast (2025–2033)

According to Renub Research, the Saudi Arabia Diabetes Drug Market is projected to rise from US$ 773.6 million in 2024 to US$ 1,331.60 million by 2033, growing at a CAGR of 6.22% from 2025 to 2033. This growth is driven by increasing diabetes prevalence, government-led public health initiatives, expanded healthcare investment, and rising adoption of modern therapeutics such as SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and biosimilar insulins.

Saudi Arabia is among the countries with the highest diabetes burden globally, making diabetes management a national priority. Structural healthcare reforms, under Vision 2030, are pushing for improved chronic disease management, early detection programs, and widespread access to innovative treatments. As a result, the demand for traditional as well as next-generation diabetes drugs continues to escalate across the Kingdom.

Saudi Arabia Diabetes Drug Market Overview

Diabetes drugs encompass a broad range of therapies used to regulate blood glucose levels in individuals with Type 1 and Type 2 diabetes. These include:

• Insulin therapies
• Oral hypoglycemic agents (metformin, sulfonylureas, meglitinides)
• SGLT2 inhibitors
• GLP-1 receptor agonists
• DPP-4 inhibitors
• Biosimilar and analog insulin formulations

In Saudi Arabia, diabetes has become a public health challenge due to sedentary lifestyles, high caloric intake, obesity, and genetic predisposition. As diagnostic technology and awareness improve, more individuals are being screened and diagnosed earlier, increasing the need for both acute and long-term drug therapy.

Government initiatives such as Vision 2030, the National Transformation Program (NTP), and large-scale screening campaigns are expanding access to diabetes care. Digital health systems, telemedicine adoption, and improved pharmaceutical distribution have also strengthened treatment adherence and expanded the demand for advanced therapeutics.

Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=saudi-arabia-diabetes-drugs-market-p.php

Market Growth Drivers

1. Rising Diabetes Prevalence in the Population

Saudi Arabia has one of the world’s highest diabetes rates. Factors such as obesity, genetic predisposition, urbanization, and poor dietary habits continue to drive new diagnoses. Current assessments show:

• Around 4.27 million people in Saudi Arabia are living with diabetes today.
• This number will rise to 5.6 million by 2030 and 7.5 million by 2045.
• At least 1.86 million individuals remain undiagnosed, indicating significant unmet medical needs.

The prevalence is high across all age groups, but particularly among middle-aged and elderly populations. Early detection, growing awareness programs, and increased screening availability have driven greater demand for oral antidiabetics, insulin therapies, and combination drugs.

The disease burden—where more than 1 in 10 individuals is diabetic—directly fuels market expansion as consistent medication remains essential for lifelong management.

2. Major Government Healthcare Investments and Awareness Initiatives

Saudi Arabia’s Vision 2030 framework emphasizes strengthening public health and chronic disease management. The Ministry of Health has invested heavily in:

• expanding hospital infrastructure
• subsidizing diabetic medications
• implementing nationwide education campaigns
• integrating diabetes management into primary healthcare
• improving access to diagnostics and monitoring

The government allocates 25–35% of healthcare spending to diseases linked to diabetes and obesity, including cardiovascular conditions. Preventive policies such as:

• a 50% tax on sugary soft drinks, and
• a 100% tax on high-sugar energy drinks

highlight the Kingdom’s commitment to reducing diabetes risk factors.

These public health initiatives boost early diagnosis, treatment adherence, and wider access to advanced diabetic medications, especially in underdeveloped regions. As a result, the demand for insulin, oral drugs, and injectables continues to grow.

3. Expanding Use of Advanced Therapeutics

Saudi Arabia’s diabetes drug landscape is transitioning rapidly from conventional treatments to modern, more effective therapeutics. High adoption rates of:

• GLP-1 receptor agonists
• SGLT2 inhibitors
• DPP-4 inhibitors
• biosimilar insulin variants

are reshaping treatment protocols. These advanced agents offer benefits such as:

• weight reduction
• cardiovascular protection
• lower hypoglycemia risk
• improved glycemic stability
• combination therapy convenience

Physician confidence in advanced therapies is growing, supported by strong clinical outcomes. The rise in local manufacturing also plays a role: for example, in October 2024, a major agreement between NUPCO, Sudair Pharmaceutical, Sanofi, and Novo Nordisk was signed to localize the production of select insulin products in the Kingdom. This enhances drug availability while lowering long-term dependency on imports.

Market Challenges

1. High Cost of Newer Diabetes Medications

Although metformin, sulfonylureas, and other traditional oral agents remain widely affordable, newer therapeutic classes—especially GLP-1 agonists, biosimilar insulin, and SGLT2 inhibitors—are significantly more expensive.

Challenges include:

• high out-of-pocket costs for uninsured patients
• limited affordability in low-income and rural segments
• reduced long-term adherence due to cost burdens
• higher price points for biologics and injectable therapies

Despite government subsidies, sustained lifelong therapy presents financial pressure for many patients, limiting the adoption of advanced drug classes.

2. Limited Diabetes Awareness and Screening in Rural Areas

Urban regions such as Riyadh, Jeddah, and Dammam have high-quality healthcare infrastructure, but rural and remote areas still suffer from:

• delayed diagnosis
• limited screening services
• inadequate awareness of symptoms and complications
• limited availability of specialists
• lower adoption of modern therapeutics

This urban-rural disparity reduces the potential market size and delays treatment initiation. Addressing these gaps through mobile clinics, telemedicine, and targeted screening campaigns is essential to expanding drug uptake across the Kingdom.

Segment Analysis

Saudi Arabia Insulin Drug Market

Insulin remains essential for all Type 1 and advanced Type 2 diabetes cases. Growth is driven by:

• rising diagnosis rates
• improved patient education
• wider adoption of analogue and long-acting insulins
• expansion of biosimilar insulin availability
• integration of CGM (continuous glucose monitoring) systems

Government subsidies are improving accessibility, ensuring strong long-term demand.

Saudi Arabia DPP-4 Inhibitors Market

DPP-4 inhibitors such as sitagliptin and linagliptin are popular due to:

• low risk of hypoglycemia
• suitability for elderly and obese patients
• oral administration convenience
• favorable cardiovascular safety evidence
• frequent use in combination with metformin

This category is seeing rising prescriptions across both primary and specialist care.

Saudi Arabia Type 2 Diabetes Drug Market

Type 2 diabetes accounts for the majority of cases in Saudi Arabia. Market growth is attributed to:

• increasing obesity
• sedentary lifestyles
• urbanization
• aging population

Demand for oral drugs, insulin therapy, and combination treatments continues to rise. New drug classes targeting insulin resistance and pancreatic function are also gaining traction.

Saudi Arabia Oral Diabetes Drug Market

Oral agents dominate due to high convenience and broad availability. Key classes include:

• metformin
• sulfonylureas
• DPP-4 inhibitors
• SGLT2 inhibitors

Online pharmacy expansion and a growing retail pharmacy network support market penetration.

Saudi Arabia Intravenous Diabetes Drug Market

IV diabetes medications are primarily used in hospitals for:

• diabetic ketoacidosis
• acute glycemic management
• surgical and emergency care

Despite being a specialized segment, it is expanding with Saudi Arabia’s growing hospital infrastructure.

Distribution Channel Analysis

• Hospital Pharmacies
  Crucial for insulin, injectables, and acute care medicines.
• Retail Pharmacies
  Widely used for oral drugs and chronic treatment refills.
• Online Pharmacies
  Gaining popularity due to convenience and home delivery.

Top Regional Markets

1. Riyadh

The largest regional market, supported by advanced hospitals, high awareness, and availability of international drug brands.

2. Jeddah

Strong healthcare infrastructure and high urban diabetes prevalence drive drug demand.

3. Dhahran

Driven by Aramco-backed medical facilities, high-income residents, and access to advanced therapies.

4. Khobar and Dammam

Growing populations and rising private healthcare services support robust market expansion.

Market Segmentation

By Drug Class

• Insulin
• GLP-1 Receptor Agonists
• DPP-4 Inhibitors
• SGLT2 Inhibitors
• Others

By Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes

By Route of Administration

• Oral
• Subcutaneous
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Key Companies Covered

(With Overviews, Key Persons, Recent Developments, SWOT, and Revenue Analysis)

• Novo Nordisk
• AstraZeneca plc
• Biocon
• Sanofi
• Eli Lilly
• Johnson & Johnson
• Bristol Myers Squibb
• Novartis AG

Conclusion

Saudi Arabia’s diabetes drug market is set for strong growth through 2033, supported by rising disease prevalence, robust government healthcare initiatives, and the expanding use of modern therapeutic agents. As the country continues to enhance healthcare infrastructure, encourage early diagnosis, and promote preventive health behaviors, demand for both traditional and advanced diabetes drugs will continue its upward trajectory.